"Pharmaceutical Sales Force Structures & Strategies 1999-2000," a survey of U.S. physicians released by Newtown, PA-based pharmaceutical consulting company Scott-Levin, reveals that doctors rank Pfizer Inc.'s sales force as the most valuable. Twenty-eight physician specialty groups in nine core specialty areas – general/family practitioners, internists, pediatricians, orthopedic surgeons, obstetricians/gynecologists, psychiatrists, general surgeons, gastroenterologists and cardiologists – were surveyed for this year's study. 1999 was the fifth consecutive year New York-based Pfizer finished first across the core groups.
"Pharmaceutical Sales Force Structures & Strategies 1999-2000," a survey of U.S. physicians released by Newtown, PA-based pharmaceutical consulting company Scott-Levin, reveals that doctors rank Pfizer Inc.'s sales force as the most valuable. Twenty-eight physician specialty groups in nine core specialty areas â general/family practitioners, internists, pediatricians, orthopedic surgeons, obstetricians/gynecologists, psychiatrists, general surgeons, gastroenterologists and cardiologists â were surveyed for this year's study. 1999 was the fifth consecutive year New York-based Pfizer finished first across the core groups.
"Our annual survey has clearly established Pfizer's sales force as the industry leader," said Joy Scott, chief executive officer of Scott-Levin. "Firms with strong reputations for innovation and professionalism tend to perform better in the overall company rankings."
Karen Katen, president of U.S. Pharmaceuticals, Decatur, GA, and executive vice president of Pfizer Pharmaceuticals Group, said she was pleased with the results of the study. "Our sales representatives are on the front line in communicating advances in the understanding and treatment of diseases to millions of healthcare providers," she said. "The success of all of our products â whether internally developed or copromoted with partners â is substantially driven by the quality of their efforts."
The leading sales forces in other specialty groups were:
•Â Allergan: opthalmologists.
•Â Bristol-Myers Squibb: endocrinologists, oncologists, hematologists.
•Â Glaxo Wellcome: neurologists.
•Â Merck: cardiologists, pulmonologists, nephrologists, neurosurgeons.
•Â Wyeth-Ayerst: OB/GYNs. PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.